HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)

Market Cap	182.55B -32.1%
Revenue (ttm)	205.58B +469.5%
Net Income	4.57B +867.2%
EPS	140.00 +310.2%
Shares Out	14.04M
PE Ratio	92.86
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,330
Average Volume	117,075
Open	13,180
Previous Close	13,000
Day's Range	12,250 - 13,570
52-Week Range	12,330 - 22,250
Beta	n/a
RSI	19.60
Earnings Date	May 22, 2026

About HLB Pharmaceutical

HLB Pharmaceutical Co., Ltd, a pharmaceutical company, researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, denta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 047920

Financial Performance

In 2025, HLB Pharmaceutical's revenue was 205.58 billion, an increase of 49.97% compared to the previous year's 137.08 billion. Earnings were 4.57 billion, an increase of 126.35%.